Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Dabrowski

Physical Medicine & Rehabilitation Roseville, MI Medical Doctor

NPI 1548230253 CMS profile 205382

25100 Kelly Rd, Roseville, MI 48066

Open in the dashboard

General payments

$167,202

717 records reported · program years 2019–2025

Research payments

$15,750

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$225,137 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Edward Dabrowski of Roseville, MI is reported in the CMS Open Payments database as having received $167,202 across 717 general payments and $15,750 in research payments paid to them. Separately, studies naming them as principal investigator received $225,137 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,326 67
2024 General $18,619 124
2023 General $26,043 116
2022 General $36,163 124
2022 Research $15,750 1
2021 General $10,041 72
2020 General $6,710 49
2019 General $48,300 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Dabrowski
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Edward Dabrowski were reported at $21,326. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Edward Dabrowski Physical Medicine & Rehabilitation median Middle half National median
2019 $48,300 $133 $45–$390 $163
2020 $6,710 $88 $29–$272 $114
2021 $10,041 $116 $33–$360 $132
2022 $36,163 $123 $40–$378 $149
2023 $26,043 $131 $43–$396 $160
2024 $18,619 $141 $45–$409 $164
2025 $21,326 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ipsen Biopharmaceuticals, Inc $79,648 175 payments
  2. AbbVie, Inc. $30,618 76 payments
  3. ACADIA Pharmaceuticals Inc $15,160 24 payments
  4. Allergan Inc. $14,385 55 payments
  5. US WorldMeds, LLC $10,092 66 payments
  6. Ipsen Innovation $5,123 5 payments
  7. PTC Therapeutics, Inc. $3,238 10 payments
  8. Ipsen Pharma SAS $1,460 2 payments
  9. Merz Pharmaceuticals, LLC $1,434 30 payments
  10. Biogen, Inc. $576 22 payments
  11. Other $5,469 252 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83,347 47 payments
  2. Consulting Fee $39,165 20 payments
  3. Food and Beverage $18,238 604 payments
  4. Travel and Lodging $14,008 38 payments
  5. Honoraria $12,271 5 payments
  6. Education $173 3 payments
Products named General payments · program years 2019–2025
  1. DYSPORT $86,230 182 payments
  2. BOTOX Neuroscience $27,088 41 payments
  3. DAYBUE $11,229 19 payments
  4. BOTOX Neuroscience $10,024 15 payments
  5. MYOBLOC $8,358 49 payments
  6. ACP-101 $3,900 2 payments
  7. BOTOX Botox Therapeutic $2,335 30 payments
  8. Xeomin $1,518 27 payments
  9. VALTOCO $536 25 payments
  10. SPINRAZA $495 18 payments
  11. Other $6,311 340 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Merz Pharmaceuticals, LLC $15,750 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

1,471

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$679,370

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

16.5%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyclarys Omaveloxolone Brand 15 $467,196
Onfi Clobazam Brand 12 $56,597
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $34,127
Baclofen Generic 180 $31,550
Chlorpromazine Hcl Generic 24 $14,392
Glycopyrrolate Generic 19 $11,093
Depakote Divalproex Sodium Brand 13 $10,745
Clonazepam Generic 245 $8,340
Dantrolene Sodium Generic 76 $7,077
Carbamazepine Generic 16 $4,015

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$279,983

Of which drugs: $238,186

Medicare patients

137

Average age 45

Services billed

45,186

74 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 33%
Depression 24%
Arthritis 21%
Diabetes 13%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 26 26,360 $124,794
Injection, abobotulinumtoxina, 5 units J0586 Office 28 13,960 $90,459

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAYBUE
$9,195 — —
DYSPORT
$7,493 — 13,960
BOTOX
$358 — 26,360
SPINRAZA
$246 — —
VALTOCO
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record